Research Mentor Name
Research Mentor Email Address
Institution / Department
Childrens Hospital of Michigan
Level of Research
Emicizumab is a new monoclonal antibody developed to dtreat people with Hemophilia A, especially those with antibodies. However, breakthrough bleeding can still occur in patients taking Emicizumab. TEG is a global coagulation assay which measures coagulability through viscosity. This study describes the use of tissue factor activated TEG in measuring bleeding profiles in patients taking Emicizumab. The goal of this prospective study is to determine if TEG can be used, which variables of TEG might be useful, and how much more useful it is than the current standard, aPtt. Findings include a 25% increased R time and 24% increased K time in patients exhibiting breakthrough bleeding compared to patients not exhibiting breakthrough bleeding.
Biological Factors | Congenital, Hereditary, and Neonatal Diseases and Abnormalities | Hemic and Lymphatic Diseases | Investigative Techniques | Laboratory and Basic Science Research | Medicine and Health Sciences
VanZweden, Daniel J.; Chitlur, Meera; and Stadler, Charity J., "Thromboelastography Profiles of Hemophilia A patients on Emicizumab" (2022). Medical Student Research Symposium. 151.
Biological Factors Commons, Congenital, Hereditary, and Neonatal Diseases and Abnormalities Commons, Hemic and Lymphatic Diseases Commons, Investigative Techniques Commons, Laboratory and Basic Science Research Commons